1. Phase III randomized study of doxorubicin induction followed by either conventional cyclophosphamide, methotrexate and fluorouracil (CMF) or high dose cyclophosphamide and thiotepa with peripheral blood stem cell rescue for stage II or IIIa breast cancer (Summary last modified 05/2000) www.cancer.gov/clinical_trials [ Accessed 25/06/02]
2. Crown J Lind M Gould A Verrill M Twelves C Coleman R Perren T van Belle S Wilson C Ledermann J Barrett-Lee P Heart D Kennedy I Simmons P Mansi J Jones A Cameron D Poole C Foster L Leonard R High-dose chemotherapy (HDC) with autograft (PBP) support is not superior to cyclophosphamide (CPA), methotrexate and 5-FU (CMF) following doxorubicin (D) induction in patients (pts) with breast cancer (BC) and 4 or more involved axillary lymph nodes (4+LN): the Anglo-Celtic I study Asco Online : www.asco.org/ [Accessed 28/06/02] 2002
3. Quality of life in the Anglo-Celtic randomised trial of high dose adjuvant chemotherapy;Forbes;Breast Cancer Research and Treatment,2001
4. Rea D The Anglo-Celtic cooperative oncology group: prospective randomised evaluation of high intensity chemotherapy with peripheral blood progenitor support in patients with high risk breast cancer National Research Register: www.update-software.com/National/ResearchResults.htm Accessed 26/08/99
5. NCI high priority clinical trial - Phase III randomized comparison of high-dose chemotherapy with autologous marrow and peripheral stem-cell support vs standard-dose chemotherapy following adjuvant chemotherapy in women with stage II/IIIA breast cancer with at least 10 positive axillary nodes (last modified 09/98) www.cancer.gov/search/clinical_trials [Accessed 28/06/02]